couter

HDIIHypertension Diagnostics, Inc.

Oct 15, 2026 — Speculative M&A / Reverse Merger Update
Chart by TradingView

The schedule

  • Thu15Oct

    Potential disclosure of a reverse merger or letter of intent (LOI), a primary catalyst for shell companies seeking operational assets. An announced combination targets a re-rating to $0.0001 from the $0.00001 base, whereas failure to secure a deal drops the valuation floor to $0.000005.

  • Tue15Dec

    Evaluation of ongoing reporting requirements and potential regulatory actions against dormant shells. Securing compliance or new sponsorship could squeeze the stock to $0.0003 from $0.0001, while regulatory clampdowns push the stock down to $0.00001.

  • Mon15Mar

    Critical deadline for sponsor extensions or capital raise efforts to keep the shell vehicle viable. Successful recapitalization targets $0.00005, while failure or highly toxic dilution forces the stock to a $0.000001 terminal floor from the $0.00001 entry.